These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 30307902)

  • 1. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
    Han CL; Zhao SL
    Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
    Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF-α is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with Kawasaki disease.
    Hu P; Jiang GM; Wu Y; Huang BY; Liu SY; Zhang DD; Xu Y; Wu YF; Xia X; Wei W; Hu B
    Clin Chim Acta; 2017 Aug; 471():76-80. PubMed ID: 28526535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
    PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM; Silverman ED; McCrindle BW; Yeung RS
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
    Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
    Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
    Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX
    Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
    Wang L; He M; Wang W; Li S; Zhao G
    Eur J Pediatr; 2024 Apr; 183(4):1765-1776. PubMed ID: 38240765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
    J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
    Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
    Li X; Tang Y; Ding Y; Chen Y; Hou M; Sun L; Qian G; Qin L; Lv H
    Eur J Pharmacol; 2021 May; 899():173985. PubMed ID: 33652059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
    Roberts SC; Jain S; Tremoulet AH; Kim KK; Burns JC; ; Anand V; Anderson M; Ang J; Ansusinha E; Arditi M; Ashouri N; Bartlett A; Chatterjee A; DeBiasi R; Dekker C; DeZure C; Didion L; Dominguez S; El Feghaly R; Erdem G; Halasa N; Harahsheh A; Jackson MA; Jaggi P; Jain S; Jone PN; Kaushik N; Kurio G; Lillian A; Lloyd D; Manaloor J; McNelis A; Michalik DE; Newburger J; Newcomer C; Perkins T; Portman M; Romero J; Ronis T; Rowley A; Schneider K; Schuster J; Tejtel SKS; Sharma K; Simonsen K; Szmuszkovicz J; Truong D; Wood J; Yeh S
    Contemp Clin Trials; 2019 Apr; 79():98-103. PubMed ID: 30840903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
    Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of early intravenous immunoglobulin therapy for Kawasaki disease: The 22nd nationwide survey in Japan.
    Kuwabara M; Yashiro M; Ae R; Yanagawa H; Nakamura Y
    Int J Cardiol; 2018 Oct; 269():334-338. PubMed ID: 30049499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.
    Burns JC; Song Y; Bujold M; Shimizu C; Kanegaye JT; Tremoulet AH; Franco A
    Clin Exp Immunol; 2013 Dec; 174(3):337-44. PubMed ID: 23901839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease.
    Vande Casteele N; Oyamada J; Shimizu C; Best BM; Capparelli EV; Tremoulet AH; Burns JC
    Clin Pharmacokinet; 2018 Dec; 57(12):1593-1601. PubMed ID: 29623653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis.
    Dionne A; Burns JC; Dahdah N; Tremoulet AH; Gauvreau K; de Ferranti SD; Baker AL; Son MB; Gould P; Fournier A; Newburger JW; Friedman KG
    Pediatrics; 2019 Jun; 143(6):. PubMed ID: 31048414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Use of Prednisolone with Intravenous Immunoglobulin for Kawasaki Disease.
    Sakai H; Iwashima S; Sano S; Akiyama N; Nagata E; Harazaki M; Fukuoka T
    Clin Drug Investig; 2021 Jan; 41(1):77-88. PubMed ID: 33341911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
    Inoue Y; Okada Y; Shinohara M; Kobayashi T; Kobayashi T; Tomomasa T; Takeuchi K; Morikawa A
    J Pediatr; 2006 Sep; 149(3):336-341. PubMed ID: 16939743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.